Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease

American Journal of Epidemiology

Volumn 164, Issue 1, 2006, Pages 56-62

  Weiss, Jocelyn M ^a,b,e   Saltzman, Babette S ^a,b   Doherty, Jennifer A ^a   Voigt, Lynda F ^a,b   Chen, Chu ^a,b,c   Beresford, Shirley A A ^a,b   Hill, Deirdre A ^d   Weiss, Noel S ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Endometrial neoplasms; Neoplasm invasiveness

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT;

CANCER; ETIOLOGY; RISK FACTOR; TUMOR;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER REGISTRY; CANCER RISK; CARCINOGENESIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBESITY; RISK FACTOR; TUMOR VOLUME;

AGED; BODY MASS INDEX; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; INTERVIEWS; LOGISTIC MODELS; MIDDLE AGED; OBESITY; ODDS RATIO; POSTMENOPAUSE; QUESTIONNAIRES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; WASHINGTON;

NORTH AMERICA; UNITED STATES; WASHINGTON [UNITED STATES];

EID: 33745368215     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwj152     Document Type: Article

References (49)

1. McDonald TW, Annegers JF, O'Fallon WM, et al. Exogenous estrogen and endometrial carcinoma: case-control and incidence study. Am J Obstet Gynecol 1977;127:572-80.
2. Collins J, Donner A, Allen LH, et al. Oestrogen use and survival in endometrial cancer. Lancet 1980;2:961-4.
3. Abeler VM, Kjorstad KE. Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol 1990;39:266-71.
4. Wilson TO, Podratz KC, Gaffey TA, et al. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol 1990;162:418-23; discussion 423-6.
5. Mariani A, Sebo TJ, Katzmann JA, et al. Pretreatment assessment of prognostic indicators in endometrial cancer. Am J Obstet Gynecol 2000;182:1535-44.
6. Alektiar KM, McKee A, Lin O, et al. The significance of the amount of myometrial invasion in patients with stage IB endometrial carcinoma. Cancer 2002;95:316-21.
7. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976;294:1262-7.
8. Gray LA Sr, Christopherson WM, Hoover RN. Estrogens and endometrial carcinoma. Obstet Gynecol 1977;49:385-9.
9. Antunes CM, Strolley PD, Rosenshein NB, et al. Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med 1979;300:9-13.
10. Hulka BS, Kaufman DG, Fowler WC Jr, et al. Predominance of early endometrial cancers after long-term estrogen use. JAMA 1980;244:2419-22.
11. Smith DC, Prentice RL, Bauermeister DE. Endometrial carcinoma: histopathology, survival, and exogenous estrogens. Gynecol Obstet Invest 1981;12:169-79.
12. La Vecchia C, Franceschi S, Gallus G, et al. Prognostic features of endometrial cancer in estrogen users and obese women. Am J Obstet Gynecol 1982;144:387-90.
13. Nyholm HC, Nielsen AL, Norup P. Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: comparison of clinical and histopathological characteristics. Gynecol Oncol 1993;49:229-35.
14. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol 1993;81:265-71.
15. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol 2004;35:649-62.
16. Sherman ME, Sturgeon S, Brinton LA, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 1997;10:963-8.
17. Sturgeon SR, Sherman ME, Kurman RJ, et al. Analysis of histopathological features of endometrioid uterine carcinomas and epidemiologic risk factors. Cancer Epidemiol Biomarkers Prev 1998;7:231-5.
18. Doherty JA, Weiss NS, Freeman RJ, et al. Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 2005;14:357-66.
19. Reed SD, Voigt LF, Beresford SA, et al. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer. Am J Obstet Gynecol 2004;191:1146-51.
20. Hill DA, Weiss NS, Beresford SA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000;183:1456-61.
21. Beresford SA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-61.
22. Shapiro JA, Weiss NS, Beresford SA, et al. Menopausal hormone use and endometrial cancer, by tumor grade and invasion. Epidemiology 1998;9:99-101.
23. Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results Program: a national resource. Cancer Epidemiol Biomarkers Prev 1999;8:1117-21.
24. Waksberg J. Sampling methods for random digit dialing. JAm Stat Soc 1978;73:40-6.
25. Marchbanks PA, McDonald JA, Wilson HG, et al. The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results. Ann Epidemiol 2002;12:213-21.
26. Beresford SA, Coker AL. Pictorially assisted recall of past hormone use in case-control studies. Am J Epidemiol 1989;130:202-5.
27. Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health-related information. Am J Epidemiol 1982;116:114-22.
28. Strom BL, Schinnar R. An interview strategy was critical for obtaining valid information on the use of hormone replacement therapy. J Clin Epidemiol 2004;57:1210-13.
29. Jain MG, Rohan TE, Howe GR. Agreement of self-reported use of menopausal hormone replacement therapy with physician reports. Epidemiology 1999;10:260-3.
30. Lurain JR. Uterine cancer. In: Berek JS, Adashi EY, Hillard PA, eds. Novak's gynecology. Baltimore, MD: Williams & Wilkins, 1996:1057-110.
31. Cook LS, Doherty JA, Weiss NS, et al. Endometrial cancer: epidemiology and molecular endocrinology. In: Henderson BE, Ponder B, Ross RK, eds. Hormones, genes, and cancer. New York, NY: Oxford University Press, Inc, 2003:371-97.
32. Cook LS, Weiss NS. Endometrial cancer. In: Goldman MB, Hatch MC, eds. Women and health. London, United Kingdom: Academic Press, 1999:916-31.
33. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
34. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-53.
35. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
36. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7.
37. Weiss NS, Szekely DR, English DR, et al. Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA 1979;242:261-4.
38. Smith DC, Prentice R, Thompson DJ, et al. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164-7.
39. Underwood PB Jr, Miller MC, Kreutner A Jr, et al. Endometrial carcinoma: the effect of estrogens. Gynecol Oncol 1979;8:60-73.
40. Abeler VM, Vergote IB, Kjorstad KE, et al. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer 1996;78:1740-7.
41. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992;47:298-305.
42. Chen JL, Trost DC, Wilkinson EJ. Endometrial papillary adenocarcinomas: two clinicopathological types. Int J Gynecol Pathol 1985;4:279-88.
43. Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
44. Aquino-Parsons C, Lim P, Wong F, et al. Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma: treatment implications. Gynecol Oncol 1998;71:83-6.
45. Hendrickson M, Ross J, Eifel PJ, et al. Adenocarcinoma of the endometrium: analysis of 256 cases with carcinoma limited to the uterine corpus. Pathology review and analysis of prognostic variables. Gynecol Oncol 1982;13:373-92.
46. Lauchlan SC. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med 1981;105:615-18.
47. Walker AN, Mills SE. Serous papillary carcinoma of the endometrium. A clinicopathologic study of 11 cases. Diagn Gynecol Obstet 1982;4:261-7.
48. Sutton GP, Brill L, Michael H, et al. Malignant papillary lesions of the endometrium. Gynecol Oncol 1987;27:294-304.
49. Creasman WT, Kohler MF, Odicino F, et al. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 2004;95:593-6.